Amarin | AMRN - Ebitda

Stock Price
14.56
Daily Change
-0.22 -1.49%
Monthly
-1.09%
Yearly
37.62%
Q2 Forecast
14.12

Amarin reported $12.54M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 5.3B 530M Mar/2026